Their two-year terms will all begin this month during the AACI/Cancer Center Administrators Forum Annual Meeting. Also at the meeting, George Weiner, MD, Director of the Holden Comprehensive Cancer Center, the C.E. Block Chair of Cancer Research, Professor of Internal Medicine, and a faculty member in the Interdisciplinary Graduate Program in Immunology at the University of Iowa, will begin his two-year term as AACI President. He was elected in 2012 (OT 2/25/13 issue).
Margaret Foti, PhD, Chief Executive Officer of the American Association for Cancer, has received the Ellen V. Sigal Advocacy Leadership Award from Friends of Cancer Research. The award from the national advocacy organization honors an advocate who has made “unprecedented” contributions to the cancer research community.
“[Foti's] dedication to cancer research, trailblazing work as CEO of the AACR, and steadfast advocacy for science and patients is unparalleled and invaluable to all in the community,” Ellen Sigal, PhD, Chairperson and Founder of Friends of Cancer Research, for whom the award is named, said in a news release.
During Foti's tenure as CEO, AACR membership has grown from 3,000 to more than 35,000. In addition to her leadership at the AACR, Foti has been elected president of three professional societies in scholarly publishing and cancer research. She has also served as a board member, committee member, and consultant to several other nonprofit, scientific, and cancer-related organizations, and is a founding board member and member of the Executive Committee of Friends of Cancer Research.
Wafik El-Deiry, MD, PhD, FACP, is now Deputy Director for Translational Research and co-Program Leader inDevelopmental Therapeutics at Fox Chase Cancer Center. He was previously at Penn State University's Milton S. Hershey Medical Center, Penn State College of Medicine, where he was the Rose Dunlap Professor of Medicine and Chief of the Hematology-Oncology Division, as well as Associate Director for Translational Research and Program Leader of Experimental Therapeutics at Penn State Cancer Institute.
He is one of 40 active American Cancer Society Research Professors, and had been Interim Cancer Center Director at Penn State from 2013 to 2014. He continues as Editor-in-Chief of the journal Cancer Biology and Therapy, and was inducted as a Member of the Johns Hopkins University Society of Scholars earlier this year.
As a practicing physician-scientist, he specializes in colorectal cancer, and leads several clinical trials for this patient population.
Dominica Anderson, a certified nursing assistant at the University of Texas MD Anderson Cancer Center, has received the Julie and Ben Rogers Award for Excellence in Patient Care from the institution. The award recognizes employees who consistently demonstrate excellence in their work and dedication to MD Anderson's mission to end cancer. She received $15,000 and a certificate of merit.
Additionally, four finalists were also recognized, and each received $1,500 and a certificate of merit. Those finalists were:
- Thomas Aloia, MD, Associate Professor of Surgery and Surgical Oncology, Deputy Chair for Education, Associate Director of the Gastrointestinal Program, and Director of Hepato-Pancreato-Biliary Surgery and International Surgical Oncology Fellowships;
- Maria Cielo Foudray, RN, Senior Leukemia Research Nurse;
- Ellen Manzullo, MD, Professor and Deputy Clinical Division Head of Internal Medicine, Clinical Deputy Chair of General Internal Medicine, and Chief of the Section for General Internal Medicine; and
- Nancy Perrier, MD, the Walter and Ruth Sterling Endowed Professor, Professor of Surgical Oncology, Chief of the Section of Surgical Endocrinology, Director of the Surgical Endocrinology Fellowship Training Program, and Associate Director of the Multidisciplinary Endocrine Center.
The Broach Foundation for Brain Cancer Research has made a $5 million commitment to support glioblastoma multiforme research at the University of Texas MD Anderson Cancer Center.
The Foundation's inaugural grant in 2012 funded research led by Frederick Lang, MD, Professor and Director of Clinical Research in Neurosurgery, which focuses on a viral smart bomb developed at MD Anderson, Delta-24-RGD, a type of cold virus engineered to infect and kill tumor cells. This most recent funding will continue to support that and other research.
In recognition of the gift, MD Anderson has named one patient pod in memory of the late James Broach and a second pod in honor of the foundation established by James and his wife Jamie in 2011, months after he received his diagnosis.
City of Hope has received a $2.5 million gift from the Panda Charitable Foundation to help launch its new Program in Natural Therapies, which will help researchers investigate the potential of foods and other plant-based ingredients to fight disease. The gift will specifically expedite the testing of promising novel therapies from three researchers who are investigating natural products' abilities to treat cancer:
- John Yim, MD, Associate Professor and Surgeon in the Division of Surgical Oncology, who is studying the effects of the compound baicalein, found in thyme and the Chinese herb huang qin, which has been shown to slow the growth of tumors in mouse models of breast cancer and shrink the tumors when used in conjunction with the chemotherapy drug cisplatin;
- David Horne, PhD, Interim Director of the Beckman Research Institute, who is researching the anti-cancer potential of a compound, known as ETP, made by fungi, which he and his team redesigned to develop an extremely potent new drug candidate; and
- Shiuan Chen, PhD, Professor and Chair in the Department of Cancer Biology, who has been exploring the potential of compounds in certain foods (including blueberries and mushrooms) to fight prostate and breast cancer.
The American Association for Cancer Research is accepting submissions for ideas for the Stand Up To Cancer-American Cancer Society Lung Cancer Translational Research Dream Team Grant, which will offer up to $20 million in research funding (with ACS and SU2C each providing half the funding over a three-year period). Bristol-Myers Squibb is also providing $5 million in funding to support the Dream Team.
The grant is intended to support projects that include therapeutic interventions for lung cancer and that deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional “Dream Team” of experts—and it is expected that new immunological approaches will be involved, a news release notes.
A SU2C-ACS Joint Scientific Advisory Committee comprised of researchers, physician-scientists, and advocates will conduct a multistep scientific review process to evaluate the applications. The committee is chaired by Phillip A. Sharp, PhD, Institute Professor at the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.
Letters of intent for the grant are due by noon (ET), Nov. 5, 2014. Further details are available at www.aacr.org/su2cfunding/dreamteam.
AACR is also now accepting submission ideas for the SU2C-Ovarian Cancer Research Fund-Ovarian Cancer National Alliance-National Ovarian Cancer Coalition Translational Research Dream Team Grant, which will provide up to $6 million in funding over three years for research projects that must include therapeutic interventions for ovarian cancer and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional Dream Team of experts.
Proposals for the grant must describe plans indicating how the group will use a transformative and synergistic approach, and how the work will be translated into the clinic, and the projects should span multiple disciplines and use modern scientific tools to attack research questions in a coordinated effort.
A Joint Scientific Advisory Committee appointed by SU2C, OCRF, OCNA, and NOCC will conduct a “unique, interactive, rapid, and rigorous” evaluation of the applications via a multistep scientific review process.
The committee is chaired by Arnold J. Levine, PhD, Professor at the Institute for Advanced Study in Princeton, New Jersey, and at the Cancer Institute of New Jersey.
Letters of intent for the grant are due by noon (ET), Nov. 7, 2014. Additional details are available at www.aacr.org/su2cfunding/dreamteam.
Elizabeth Whelan Dies at 70
Elizabeth M. Whelan, MPH, MS, ScD, Founder and President of the American Council on Science and Health (ACSH), died in September. She was 70.
“She was an inspirational, amazing person, who was passionately dedicated to ACSH's mission,” Cheryl Martin, ACSH Associate Director and Director of Development, said in a statement. “She was truly science-driven on every issue, and uncompromising in her effort to ensure that science always prevailed, despite considerable obstacles. She dedicated her life so unselfishly to the greater public good.”
Whelan founded the ACSH in 1978 to promote “sound science” and independent peer review in public health. She recruited hundreds of scientists to join the initiative including: Norman E. Borlaug, PhD, who had received the Nobel Peace Prize in 1970 for his contributions to increase global grain yields; Fredrick J. Stare, PhD, who founded the nutrition department at Harvard School of Public Health; and others.
Whelan wrote or co-wrote 27 books, mostly on nutrition, smoking, or environmental issues including The Complete Guide to Cancer Prevention, Panic in the Pantry: Facts & Fallacies about the Food You Buy, and Toxic Terror.
Share Your News!
Send information and photos for this column to OT@LWWNY.com© 2014 by Lippincott Williams & Wilkins, Inc.
More on ONCOLOGY-TIMES.com...